‘Definitive test’ finds exercise a potent weapon against colon cancer
On Jun. 2, 2025, a first-of-its-kind international trial provides definitive evidence that people who follow a structured exercise program…
University of Alberta life sciences research gets a $100 Million lift
On Mar. 4, 2025, the Government of Alberta announced it had contributed $100 million in capital funding to…
Breast cancer is on the rise: data reveal drastic gap in survival rates
On Feb. 24, 2025, breast cancer is the most common cancer in women worldwide, but survival chances vary…
Alberta researchers genetically engineer yeast to produce healthy fatty acid
On Jan. 21, 2025, researchers from the University of Alberta announced they have come up with a way…
Biotechnology | Diagnostics | Disease | Genomics | Neurology | Therapeutics
Alberta researchers revealed full structure of ‘ancient genetic parasite’ implicated in human diseases
On Dec. 14, 2023, the University of Alberta announced that a study published in Nature sheds light on…
Biotechnology | CDC | Diagnostics | Infectious Disease | Measles | Vaccine
Passenger with measles travelled through Vancouver International Airport
On Nov. 29, 2023, the BC Centre for Disease Controlr Disease Control (BCCDC) announced that a A passenger…
Alberta Innovates invested $13.6 million to strengthen Alberta’s technology sector
On Aug. 22, 2023, Alberta Innovates announced that more than $13.6 million will go to 19 partners, across…
Highly pathogenic avian influenza reported in Alberta
On Apr. 12, 2022, the Province of Alberta poultry reported that farms had tested positive for highly pathogenic…
Resverlogix expanded phase 2b clinical trial for COVID-19 treatment with first site in Brazil and second in Canada
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Sept. 23, 2021, Tonix Pharmaceuticals announced it had expanded its research collaboration with Columbia University. The research…
Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome
On Jun. 21, 2021, Tonix Pharmaceuticals announced that it planned to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets)…
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
Tonix Pharma reported positive COVID-19 vaccine efficacy results in non-human primates vaccinated with TNX-1800
On Mar. 17, 2021, Tonix Pharma announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate
On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Tonix Pharmaceuticals enrolled first participant in PRECISION Study for COVID-19 vaccines and therapeutics
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Jul. 16, 2020, Tonix Pharmaceuticals announced it had entered into a research collaboration and option agreement with…
Province of Alberta made 20 million masks available free of charge
On Jul. 13, 2020, 20 million masks were made available at more than 700 partner restaurant locations, including…
Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…
Government of Canada and provincial partners invested more than $109 mllion in COVID-19 research
On Jun. 25, 2020, the Government of Canada announced the results of that funding competition: an investment of…
University of Alberta researcher to test whether COVID-19 antibodies provide long-term immunity
On Jun. 25, 2020, the University of Alberta (U of A) announced a study that will analyze thousands…
Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration
On Jun. 18, 2020, Tonix Pharmaceuticals announced an expansion of its strategic collaboration with Southern Research to include…
Unique biorepository stores samples from Alberta COVID-19 patients for future research
On Jun. 5, 2020, the Alberta Precision Laboratories (APL) COVID-19 Biorepository was announced to ensure researchers have the…
Tonix Pharma announced FUJIFILM Diosynth Biotechnologies to be Manufacturing partner for COVID-19 vaccine candidate TNX-1800
On Jun. 1, 2020, Tonix Pharmaceuticals announced an agreement whereby FUJIFILM Diosynth Biotechnologies will provide contract manufacturing and…
University of Alberta researchers launched a joint effort with US-based Tonix Pharma to develop and test a vaccine against COVID-19
On May 13, 2020, University of Alberta (UA) researchers launched a joint effort with U.S.-based Tonix Pharmaceuticals to…
U of Alberta pharmaceutical institute leads effort to fill looming hospital drug shortage during fight against COVID-19
On May 11, 2020, a University of Alberta-initiated institute leads province wide effort to fill the looming shortage…
Tonix Pharma announced research collaboration and exclusive agreement with the University of Alberta to develop novel c-based vaccines for prevention of COVID-19
On May 7, 2020, Tonix Pharmaceuticals and the University of Alberta announced a research collaboration and exclusive licensing…